ERBB2 and breast cancer: In this single–center study, cases of luminal B (HER–2 negative) breast cancer at the Peking University First Hospital were retrospectively analyzed to investigate the correlation between AR and survival and neoadjuvant treatment outcomes in luminal B (HER–2 negative) breast cancer, and to determine AR cutoff values with clinical value.